Enorama Pharma AB (SE:ERMA)

:ERMA

ERMA

Enorama Pharma AB

RESEARCH TOOLSreports

Want to see SE:ERMA full AI Analyst Report?

Enorama Pharma AB (ERMA) Price & Analysis

0 Followers

ERMA Stock Chart & Stats

kr1.91

-kr0.30(-12.50%)

At close: Mar 06 4:00 PM EST

kr1.91

-kr0.30(-12.50%)

Day’s Range― - ―

52-Week Rangekr0.21 - kr3.58

Previous CloseN/A

Volume29.79K

Average Volume (3M)4.35K

Market Cap

kr20.88M

Enterprise Valuekr17.85M

Total Cash (Recent Filing)kr3.04M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.35

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding74,588,684

10 Day Avg. Volume2,975

30 Day Avg. Volume4,348

Financial Highlights & Ratios

PEG Ratio-0.06

Price to Book (P/B)-5.66

Price to Sales (P/S)48.45

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Partner/licensing-oriented Business ModelEnorama’s asset-light model focuses on licensing and partnerships rather than direct retail scale-up. That durable approach reduces fixed selling costs, leverages partners’ commercialization capacity, and lets the company capture milestone/royalty upside while limiting the need for a large sales organization.

Low Reported LeverageReported zero debt across 2024–2025 preserves financial flexibility and lowers interest burden, which is especially valuable for a development-stage pharma firm. Low leverage gives management time to progress assets before needing urgent refinancing or dilutive capital, supporting survival through development cycles.

Proprietary NRT Formulations And Focused IPA concentrated IP portfolio and technical focus on nicotine replacement delivery create structural barriers to entry and make the company an attractive partner for larger players. Durable competitive advantage comes from patented formulations, specialized know‑how and the ability to license technology rather than build full commercial infrastructure.

Bears Say

Negative Shareholders' EquityEquity turning negative materially weakens the balance sheet cushion and increases funding risk. Over the medium term this constrains strategic optionality, can complicate partner negotiations, and heightens the likelihood of needing dilutive capital or restructuring to sustain development programs.

Persistent Operating Cash BurnConsistent and worsening negative operating cash flow signals structural cash consumption from R&D and operations. Without positive operating cash generation, the company will depend on external financing or milestone receipts, creating dilution risk and potentially delaying development or partner-driven commercialization timelines.

Shrinking Revenue And Widening LossesA sharp top-line decline coupled with deteriorating margins reflects unstable commercialization or partner revenue flows and weak operational scalability. Over 2–6 months this reduces runway visibility, pressures cash needs, and undermines the company’s ability to fund trials or attract favorable licensing terms.

ERMA FAQ

What was Enorama Pharma AB’s price range in the past 12 months?

Enorama Pharma AB lowest stock price was kr0.21 and its highest was kr3.58 in the past 12 months.

What is Enorama Pharma AB’s market cap?

Enorama Pharma AB’s market cap is kr20.88M.

When is Enorama Pharma AB’s upcoming earnings report date?

Enorama Pharma AB’s upcoming earnings report date is May 20, 2026 which is in 20 days.

How were Enorama Pharma AB’s earnings last quarter?

Enorama Pharma AB released its earnings results on Feb 18, 2026. The company reported -kr0.276 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.276.

Is Enorama Pharma AB overvalued?

According to Wall Street analysts Enorama Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enorama Pharma AB pay dividends?

Enorama Pharma AB does not currently pay dividends.

What is Enorama Pharma AB’s EPS estimate?

Enorama Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enorama Pharma AB have?

Enorama Pharma AB has 74,588,684 shares outstanding.

What happened to Enorama Pharma AB’s price movement after its last earnings report?

Enorama Pharma AB reported an EPS of -kr0.276 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 22.613%.

Which hedge fund is a major shareholder of Enorama Pharma AB?

Currently, no hedge funds are holding shares in SE:ERMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enorama Pharma AB

Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven generic substances in Sweden. It offers nicotine chewing gum for smoking cessation and medical cannabis chewing gums for non-pharma applications, as well as for other applications, such as oromucosal drug delivery and allergic rhinitis. The company is based in Malmö, Sweden.